David Nassif

David W.
Nassif currently works at Sio Gene Therapies, Inc., as CEO, CFO, Director, CAO & General Counsel from 2022 and Pharvaris NV, as Chief Financial & Legal Officer, Secretary from 2024.
Mr. Nassif also formerly worked at Cypros Pharmaceutical Corp., as Chief Financial Officer & Senior Vice President from 1993 to 1999, Zaldiva, Inc., as Chief Financial Officer, Zogenix, Inc., as CFO, Secretary, Treasurer & Executive VP in 2010, Amphastar Pharmaceuticals, Inc., as Chief Financial Officer & SVP-Global Licensing from 2002 to 2006, RealAge, Inc., as Chief Financial Officer & Senior Vice President from 2000 to 2001, Strategic Consulting Services, as Principal from 2001 to 2002, Strategic Consulting Services, as Principal in 2006, Histogen, Inc., as President & Chief Financial Officer from 2011 to 2014, SteadyMed Ltd., as Chief Financial Officer & Executive Vice President from 2015 to 2019, and Axovant Sciences, Inc., as Chief Financial Officer from 2019 to 2020.
Mr. Nassif received his undergraduate degree from the University of Virginia and graduate degree from the University of Virginia School of Law.